Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
The AlloVir, Inc. (ALVR) news page on Stock Titan aggregates company communications and third-party coverage related to its activities as an allogeneic T cell immunotherapy developer and its planned merger with Kalaris Therapeutics, Inc. AlloVir describes itself as a late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised pediatric and adult patients. Its disclosures highlight an off-the-shelf, allogeneic virus-specific T cell platform and a pipeline led by the multi-virus-specific T cell therapy posoleucel.
Readers following ALVR news can find updates on clinical trial progress and outcomes, including Phase 2 and Phase 3 studies of posoleucel in allogeneic hematopoietic cell transplant recipients and adult kidney transplant recipients with BK viremia. Company releases have discussed prevention and treatment trials targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus, as well as early-stage work on ALVR106 for respiratory viruses and ALVR107 for chronic hepatitis B infection.
News items also cover strategic and corporate developments. AlloVir has reported discontinuation of its three Phase 3 posoleucel studies after pre-planned futility analyses, along with a shift toward capital preservation and review of strategic alternatives. Subsequent announcements describe a definitive all-stock merger agreement with Kalaris Therapeutics, stockholder approval of that merger, and expectations that the combined company will operate as Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker KLRS, subject to customary closing conditions.
In addition, the ALVR news feed may include information on financings, investor conference participation, and regulatory designations such as RMAT, Orphan Drug, and PRIME status for posoleucel. Investors and researchers can use this page to monitor how AlloVir’s virus-specific T cell programs and its transition toward a retina-focused combined company with Kalaris are described over time.
AlloVir has received FDA clearance for its Investigational New Drug application regarding ALVR109, an allogeneic virus-specific T cell therapy aimed at treating high-risk COVID-19 patients. This therapy targets SARS-CoV-2 to potentially halt disease progression. Clinical trials are set to begin in Q4 2020, following resolution of prior manufacturing hold issues. The company continues to collaborate with Baylor College of Medicine to leverage T cell responses in combating COVID-19, focusing on patients with reduced T cell counts that correlate with lower survival rates.
AlloVir (Nasdaq: ALVR) has appointed Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer, a new role aimed at enhancing its regulatory strategy. Dr. Atillasoy's nearly 25 years of experience includes senior roles at Merck, overseeing significant infectious disease products and regulatory engagements worldwide. His expertise is expected to support AlloVir's late-stage clinical trials targeting life-threatening viral diseases. This strategic hire reflects AlloVir's commitment to advancing its innovative cell therapy pipeline.
AlloVir (Nasdaq: ALVR) has successfully closed its upsized initial public offering of 18,687,500 shares of common stock at $17.00 per share, generating approximately $317.7 million in gross proceeds. The offering included the full exercise of underwriters' options for an additional 2,437,500 shares. This capital infusion will support AlloVir's late-stage clinical trials aimed at restoring immunity in patients with weakened immune systems through innovative cell therapies targeting viral diseases. The offering was facilitated by Morgan Stanley, J.P. Morgan, SVB Leerink, and Piper Sandler & Co.
AlloVir, Inc. (Nasdaq: ALVR) has priced its upsized initial public offering at $17.00 per share, offering 16,250,000 shares of common stock. The total gross proceeds from the offering are projected to be $276.25 million before expenses. Trading began on July 30, 2020, with closing expected on August 3, 2020. A 30-day underwriters’ option exists for an additional 2,437,500 shares. The offering is managed by Morgan Stanley, J.P. Morgan, SVB Leerink, and Piper Sandler.